CEL-SCI Corp
$ 1.25
-1.57%
21 Jul - close price
- Market Cap 22,196,000 USD
- Current Price $ 1.25
- High / Low $ 1.33 / 1.21
- Stock P/E N/A
- Book Value 0.81
- EPS -2.15
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.70 %
- ROE -3.05 %
- 52 Week High 13.48
- 52 Week Low 0.89
About
CEL-SCI Corporation is dedicated to the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia.
Analyst Target Price
$15.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-12 | 2025-12-23 | 2025-08-14 | 2025-05-14 | 2025-01-13 | 2024-12-31 | 2024-08-14 | 2024-05-16 | 2024-02-14 | 2023-12-22 | 2023-08-11 | 2023-05-12 |
| Reported EPS | -0.68 | -0.86 | -1.36 | -2.3323 | -2.7 | -2.7003 | -4.2 | -8.4 | -4.2 | -0.16 | -5.7 | -5.7 |
| Estimated EPS | 0 | None | None | None | -3.3 | -0.1 | -3.9 | -4.2 | -4.2 | -0.16 | -4.5 | -5.1 |
| Surprise | -0.68 | 0 | 0 | 0 | 0.6 | -2.6003 | -0.3 | -4.2 | 0 | 0 | -1.2 | -0.6 |
| Surprise Percentage | None% | None% | None% | None% | 18.1818% | -2600.3% | -7.6923% | -100% | 0% | 0% | -26.6667% | -11.7647% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CVM
2026-07-13 16:10:43
CEL-SCI Corporation (NYSE American: CVM) is launching a global Confirmatory Registration Study for its investigational immunotherapy, Multikine®, to treat newly diagnosed, untreated, resectable, locally advanced primary head and neck cancer. This 212-patient study aims to confirm previous Phase 3 results showing a significant reduction in the risk of death and increased 5-year survival rates in a specific patient population. The company intends to leverage early pre-surgical tumor responses for potential accelerated or conditional FDA approval, targeting a critical need for non-toxic neoadjuvant immunotherapies in head and neck cancer.
2026-07-13 12:09:53
CEL-SCI Corporation is launching a global, 212-patient Confirmatory Registration Study for its investigational cancer immunotherapy, Multikine, as a neoadjuvant treatment for newly diagnosed, previously untreated, resectable, locally advanced primary head and neck cancer. The study will enroll patients in the U.S., Europe, Asia, and South America, aiming to confirm a significant reduction in the risk of death and increased five-year survival rates previously observed in a specific patient cohort. CEL-SCI plans to use early pre-surgical objective response endpoints to support potential accelerated or conditional FDA approval.
2026-07-04 00:12:16
This article provides the latest SEC filings and comprehensive financial data for Cel-Sci Corp (CVM). It details the company's financial metrics, stock performance, insider and institutional ownership, and analyst recommendations. The data includes market capitalization, income, sales, various ratios, EPS figures, and historical performance over different periods.
2026-07-02 21:10:48
This article reports on a CEL SCI CORP (CVM) SEC Filing, specifically Form ARS, which has a low impact and neutral sentiment according to Rhea-AI. The filing was accepted by SEC EDGAR on July 2, 2026, at 05:07 PM. The article provides details on the company's stock data, recent news, and other SEC filings.
2026-07-02 21:10:48
CEL-SCI Corporation has scheduled its 2026 annual shareholder meeting for August 14, 2026, where shareholders will vote on key proposals including the election of directors, approval of new 2026 Non-Qualified Stock Option and Stock Bonus Plans, and advisory votes on executive compensation and frequency. The company reported 17,477,144 common shares outstanding as of June 18, 2026, and disclosed CEO total compensation of $919,854 for 2025. The Board recommends approving the equity plans, executive compensation, and holding future say-on-pay votes every three years, as well as ratifying BDO USA, P.C. as the independent auditor.
2026-07-01 13:38:00
This article announces the filing of Form 4 for CEL-SCI Corp on July 1st, published by Investing.com. It is a brief corporate news item indicating an insider transaction report for the specified date. The piece provides the company's stock symbol (CVM) and its price performance at the time of publication, which was up 8.57%.
